Corcept Therapeutics (NASDAQ:CORT) Director G Leonard Baker, Jr. Purchases 100,000 Shares

Corcept Therapeutics Incorporated (NASDAQ:CORT) Director G Leonard Baker, Jr. bought 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was purchased at an average cost of $33.14 per share, for a total transaction of $3,314,000.00. Following the completion of the transaction, the director owned 1,146,631 shares in the company, valued at $37,999,351.34. This trade represents a 9.55% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Corcept Therapeutics Stock Up 2.3%

Corcept Therapeutics stock opened at $34.08 on Friday. The business’s 50-day simple moving average is $37.52 and its two-hundred day simple moving average is $62.18. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 2.92. The company has a market cap of $3.63 billion, a PE ratio of 41.56 and a beta of 0.29. Corcept Therapeutics Incorporated has a fifty-two week low of $28.66 and a fifty-two week high of $117.33.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The firm had revenue of $202.13 million for the quarter, compared to analyst estimates of $254.94 million. During the same period last year, the firm earned $0.26 EPS. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. Equities analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on CORT. UBS Group began coverage on shares of Corcept Therapeutics in a report on Tuesday, December 16th. They set a “neutral” rating and a $95.00 target price for the company. Zacks Research lowered shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Canaccord Genuity Group increased their price target on Corcept Therapeutics from $99.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, January 23rd. Weiss Ratings reissued a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. Finally, HC Wainwright dropped their target price on Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Corcept Therapeutics currently has an average rating of “Hold” and a consensus target price of $77.17.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Director G. Leonard Baker Jr. purchased 100,000 CORT shares (~$3.3M) on March 17, increasing his stake by ~9.6%, a signal of insider confidence that can support the stock. SEC Form 4
• Neutral Sentiment: Reported short‑interest data show effectively zero reported short interest as of March 19 (data appear anomalous), so there’s no clear short‑seller pressure signal from this release. (May reflect reporting irregularities rather than investor behavior.)
• Negative Sentiment: Hagens Berman and other firms highlight an investor suit tied to an alleged FDA rejection and a federal court patent loss — items that can materially damage future revenue expectations and investor confidence. Hagens Berman Alert
• Negative Sentiment: Multiple shareholder‑rights firms (Schall, DJS, Rosen, Pomerantz, Glancy, Levi & Korsinsky, Robbins, etc.) issued class‑action/lead‑plaintiff notices for investors who bought CORT between Oct 31, 2024 and Dec 30, 2025 — a concentrated PR wave that keeps legal risk and potential liability top of mind for the market. Representative notice: Schall Law Firm. Schall Law Firm Notice
• Negative Sentiment: Zacks Research cut its Q3 2026 EPS estimate for CORT (from $0.30 to $0.21) and carries a “Strong Sell” view — analyst downgrades and lower guidance expectations can weigh on sentiment and valuation multiples.

Institutional Trading of Corcept Therapeutics

Several institutional investors have recently bought and sold shares of the business. Royal Bank of Canada lifted its holdings in Corcept Therapeutics by 18.9% during the first quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company’s stock valued at $1,757,000 after purchasing an additional 2,444 shares in the last quarter. Amundi purchased a new position in Corcept Therapeutics in the 1st quarter valued at $450,000. NewEdge Advisors LLC acquired a new stake in Corcept Therapeutics during the 1st quarter worth $518,000. Police & Firemen s Retirement System of New Jersey boosted its stake in Corcept Therapeutics by 102.3% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 35,739 shares of the biotechnology company’s stock worth $2,623,000 after purchasing an additional 18,074 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in shares of Corcept Therapeutics by 8.6% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 24,231 shares of the biotechnology company’s stock worth $1,779,000 after buying an additional 1,916 shares in the last quarter. 93.61% of the stock is owned by institutional investors and hedge funds.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.